{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:36:03Z","timestamp":1781537763342,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.jacl.2015.01.002","type":"journal-article","created":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T08:50:47Z","timestamp":1421225447000},"page":"384-389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia"],"prefix":"10.1016","volume":"9","author":[{"given":"Hern\u00e1n N.","family":"Lemus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos O.","family":"Mendivil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2015.01.002_bib1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.01.002_bib2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.01.002_bib3","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"1","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacl.2015.01.002_bib4","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2174\/0929867311320110004","article-title":"Statin intolerance: why and what to do\u2014with a focus on diabetic people","volume":"20","author":"Matteucci","year":"2013","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jacl.2015.01.002_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijcard.2011.07.048","article-title":"Managing the underestimated risk of statin-associated myopathy","volume":"159","author":"Rallidis","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2015.01.002_bib6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/qjmed\/hcr158","article-title":"Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis","volume":"105","author":"Alberton","year":"2012","journal-title":"QJM"},{"key":"10.1016\/j.jacl.2015.01.002_bib7","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","author":"Swerdlow","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.01.002_bib8","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-014-3374-x","article-title":"Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis","author":"Erqou","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacl.2015.01.002_bib9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1185\/03007990903500565","article-title":"Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries","volume":"26","author":"Hermans","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2015.01.002_bib10","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/j.1464-5491.2011.03360.x","article-title":"Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study","volume":"28","author":"Leiter","year":"2011","journal-title":"Diabet Med"},{"key":"10.1016\/j.jacl.2015.01.002_bib11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrcardio.2014.84","article-title":"Lipid lowering with PCSK9 inhibitors","volume":"11","author":"Dadu","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacl.2015.01.002_bib12","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1194\/jlr.M003335","article-title":"Deficiency in hepatic ATP-citrate lyase affects VLDL-triglyceride mobilization and liver fatty acid composition in mice","volume":"51","author":"Wang","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2015.01.002_bib13","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1107\/S1744309111028363","article-title":"ADP-Mg2+ bound to the ATP-grasp domain of ATP-citrate lyase","volume":"67","author":"Sun","year":"2011","journal-title":"Acta Crystallogr Sect F Struct Biol Cryst Commun"},{"key":"10.1016\/j.jacl.2015.01.002_bib14","doi-asserted-by":"crossref","first-page":"27418","DOI":"10.1074\/jbc.M109.078667","article-title":"Identification of the citrate binding site of human ATP-citrate lyase using X-ray crystallography","volume":"285","author":"Sun","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2015.01.002_bib15","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1158\/0008-5472.CAN-11-4112","article-title":"ATP-citrate lyase: a key player in cancer metabolism","volume":"72","author":"Zaidi","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jacl.2015.01.002_bib16","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.3892\/or.2012.1638","article-title":"Prognostic and therapeutic implications of increased ATP citrate lyase expression in human epithelial ovarian cancer","volume":"27","author":"Wang","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1016\/j.jacl.2015.01.002_bib17","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.metabol.2014.04.003","article-title":"De novo lipogenesis in health and disease","volume":"63","author":"Ameer","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2015.01.002_bib18","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.coph.2012.06.011","article-title":"Regulation of cholesterol biosynthesis and cancer signaling","volume":"12","author":"Gorin","year":"2012","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jacl.2015.01.002_bib19","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1172\/JCI67227","article-title":"AMPK, insulin resistance, and the metabolic syndrome","volume":"123","author":"Ruderman","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2015.01.002_bib20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1467-789X.2009.00642.x","article-title":"Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome","volume":"11","author":"Schreurs","year":"2010","journal-title":"Obes Rev"},{"key":"10.1016\/j.jacl.2015.01.002_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mce.2012.06.019","article-title":"AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: implications for obesity","volume":"366","author":"O'Neill","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jacl.2015.01.002_bib22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/MOL.0000000000000091","article-title":"LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase","volume":"25","author":"Filippov","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2015.01.002_bib23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2015.01.002_bib24","doi-asserted-by":"crossref","first-page":"18707","DOI":"10.1074\/jbc.R113.479808","article-title":"Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR)","volume":"288","author":"Sharpe","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2015.01.002_bib25","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"Ballantyne","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.01.002_bib26","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1194\/jlr.M035212","article-title":"ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK","volume":"54","author":"Filippov","year":"2013","journal-title":"J Lipid Res"},{"issue":"Suppl 1","key":"10.1016\/j.jacl.2015.01.002_bib27","doi-asserted-by":"crossref","first-page":"E1463","DOI":"10.1016\/S0735-1097(13)61463-1","article-title":"ETC-1002, a modulator of adenosine monophosphate-activated protein kinase and adenosine triphosphate-citrate lyase, was safe and reduced low-density lipoprotein-cholesterol in healthy volunteers","volume":"61","author":"MacDougall","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.01.002_bib28","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1021\/jm2005805","article-title":"The lipogenesis pathway as a cancer target","volume":"54","author":"Abramson","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.jacl.2015.01.002_bib29","doi-asserted-by":"crossref","first-page":"8411","DOI":"10.1016\/S0021-9258(17)39489-9","article-title":"Inhibition of lipid synthesis by beta beta'-tetramethyl-substituted, C14-C22, alpha, omega-dicarboxylic acids in cultured rat hepatocytes","volume":"260","author":"Rose-Kahn","year":"1985","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2015.01.002_bib30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0005-2760(90)90018-S","article-title":"Inhibition of rat liver acetyl-CoA carboxylase by beta, beta'-tetramethyl-substituted hexadecanedioic acid (MEDICA 16)","volume":"1042","author":"Rose-Kahn","year":"1990","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jacl.2015.01.002_bib31","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","article-title":"Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus","volume":"34","author":"Gutierrez","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2015.01.002_bib32","unstructured":"Esperion Therapeutics: ETC-1002 phase 1 and phase 2 clinical trials, as of October 2014. Available at: http:\/\/www.esperion.com\/therapies-progress\/etc-1002\/. Accessed last time on October 10,\u00a02014."}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415000380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415000380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T20:28:08Z","timestamp":1651004888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287415000380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S1933287415000380"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2015.01.002","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2015.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 National Lipid Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}